相似文献
1
Antidepressant reformulations: who uses them, and what are the benefits?
Health Aff (Millwood). 2009 May-Jun;28(3):734-45. doi: 10.1377/hlthaff.28.3.734.
2
A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
Value Health. 2001 Jan-Feb;4(1):16-31. doi: 10.1046/j.1524-4733.2001.004001016.x.
3
An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.
J Ment Health Policy Econ. 2002 Mar;5(1):3-19.
4
Escitalopram (Lexapro) for depression.
Am Fam Physician. 2003 Dec 1;68(11):2235-6.
5
Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.
J Med Econ. 2015;18(11):919-29. doi: 10.3111/13696998.2015.1061534. Epub 2015 Jul 6.
6
Drug selection. Old versus new.
Aust Fam Physician. 1999 Oct;28(10):1036-8.
7
Discontinuation rates and health care costs in adult patients starting generic versus brand SSRI or SNRI antidepressants in commercial health plans.
J Manag Care Pharm. 2011 Mar;17(2):123-32. doi: 10.18553/jmcp.2011.17.2.123.
8
Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
J Manag Care Pharm. 2008 Jun;14(5):426-41. doi: 10.18553/jmcp.2008.14.5.426.
9
10
Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
Clin Ther. 2009 Mar;31(3):644-56. doi: 10.1016/j.clinthera.2009.03.012.
引用本文的文献
1
Drug reformulations and repositioning in pharmaceutical industry and its impact on market access: reassessment of nomenclature.
J Mark Access Health Policy. 2013 Aug 6;1. doi: 10.3402/jmahp.v1i0.21131. eCollection 2013.
2
Management of Newer Antidepressant Medications in U.S. Commercial Health Plans.
J Ment Health Policy Econ. 2015 Dec;18(4):165-73.
3
The diminished pipeline for medications to treat mental health and substance use disorders.
Psychiatr Serv. 2014 Dec 1;65(12):1433-8. doi: 10.1176/appi.ps.201400044. Epub 2014 Nov 17.
4
Medication complexity and affordability in use of time release antidepressants.
Clin Transl Sci. 2014 Oct;7(5):376-83. doi: 10.1111/cts.12174. Epub 2014 Jun 5.
5
Research article: Antidepressant use among Asians in the United States.
Depress Anxiety. 2010;27(1):46-55. doi: 10.1002/da.20636.
本文引用的文献
1
Generic entry, reformulations and promotion of SSRIs in the US.
Pharmacoeconomics. 2008;26(7):603-16. doi: 10.2165/00019053-200826070-00007.
2
Clinical improvement associated with conformance to HEDIS-based depression care.
Ment Health Serv Res. 2005 Jun;7(2):103-12. doi: 10.1007/s11020-005-3781-1.
3
Escitalopram: superior to citalopram or a chiral chimera?
Psychother Psychosom. 2004 Jan-Feb;73(1):10-6. doi: 10.1159/000074435.
4
A systematic review of the associations between dose regimens and medication compliance.
Clin Ther. 2001 Aug;23(8):1296-310. doi: 10.1016/s0149-2918(01)80109-0.
5
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group.
Stat Med. 1998 Oct 15;17(19):2265-81. doi: 10.1002/(sici)1097-0258(19981015)17:19<2265::aid-sim918>3.0.co;2-b.
Zotero 插件